A Case Challenge: Anticoagulant Choices for Acute PE

Slides:

Advertisements

Similar presentations

Farmaci usati prima dellintervento Basi farmacologiche del loro uso La prevenzione del tromboembolismo.

Advertisements

Giancarlo Agnelli Università di Perugia Anticoagulant treatment for PE: optimal duration.

VTE in abdominal-pelvic surgery patients

 Incidence rate (symptomatic): 1%  ½ occur after discharge  We don’t understand which patients are at highest risk.

DPT 732 SPRING 2009 S. SCHERER Deep Vein Thrombosis.

LIFEBLOOD THE Thrombosis CHARITY Venous thromboembolism – Treatment and secondary prevention Ulcus cruris Chronic PE PE DVT Post-thrombotic syndrome Death.

Unprovoked DVT in a young patient

Case Report Pneumology Dr. David Tran A&E, FVHospital Medical meeting September 28 th, 2011.

Respiratory CONNECT meeting Dr Julius Cairn. Risk stratification in PE Clinical parameters – shock, JVP, S3 Imaging – CTPA, echo Biomarkers – Troponin,

Risk Assessment for VTE. Which of the following best describes you?

2014 ESC guidelines update on the diagnosis and management of acute pulmonary embolism Anticoagulation for the treatment of PE and secondary prevention.

Educational Purposes. Coalition To Prevent VTE - Risk Assessment.

Venous Thromboembolic Disease: The Role of Novel Anticoagulants Grant M. Greenberg MD, MA, MHSA.

Outpatient DVT assessment & treatment Daniel Gilada.

The shock index and the simplified PESI for identification of low-risk patients with acute pulmonary embolism A.Sam, D. Sa´nchez, V. Go´mez, C. Wagner,

TREATMENT OF ACUTE PULMONARY THROMBOEMB0LISM SEYED REZA SEYEDI.MD.

Addressing the Challenges in Primary and Secondary Stroke Prevention

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

UNDERSTANDING YOUR RISK FOR DEVELOPING BLOOD CLOTS (VTE) IN CANCER

Lessons on Malignancy.

CHA2DS2-VASc Scoring System General AF Treatment Guidance.

NOACs for Cancer-Associated Thrombosis:

Anticoagulants in Interventional Cardiology:

Extended Treatment of VTE: Who is the Right Candidate?

NOACs In Long-term VTE Treatment: A State Of The Art Review

Long-Term Treatment of VTE: Case Studies

Thrombosis, Cancer, and NOACs

Introduction ESC Annual Meeting in Review: NOACs and NVAF: Real-World Data, Guidelines, and More.

Up to Date on Which NOAC for Which Patient

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Figure 3 Semantic model of the active surveillance (AS) timeline

Oral Anticoagulants in AFa,b A Brief History.

Surveying the Safety of NOACs in the Real World

Assessing the Risk for Stroke in Patients With Atrial Fibrillation

Are We Closer to Personalized Medicine in MS?

New Oral Anticoagulants and VTE Management

VTE Treatment Conventional Approach

Antithrombotic Protection in CAD and HF

Learning Objectives Classification of VTE Goals of VTE Treatment.

A Better Solution For Cancer Patients With VTE?

Real-World Evidence in VTE

Extending Treatment for Thrombosis: What’s the Right Choice?

Practical Considerations to Extend Treatment for VTE

Extraordinary Cases of VTE Prevention in Patients With Cancer

Treatment of Thromboembolic Disease The Need for Multiple Perspectives

EARLY Combination Therapy in PAH: What Every Cardiologist Needs to Know.

Taking the "Cryptogenic" Out of Cryptogenic Stroke

Anticoagulation and Thrombosis Management

Trials and Tribulations in VTE: How Do Real-World Data Fit In?

Long-Term Treatment of VTE: Case Studies

A Time for Change for Managing Patients With VTE Who Have Cancer

Cancer-Associated Thrombosis

Improving Outcomes in AF: Do the NOACs Hold Their Promise In The Real World?

Managing Pulmonary Embolism Posthospital Discharge

NOAC Studies in VTE AF Studies Superior Outcomes.

How I treat cancer-associated venous thromboembolism

Program Goals Background: Anticoagulation in Patients With VTE.

Treatment and secondary prevention strategy diagram for VTE in patients with active cancer based on the treatment guidelines for cancer-associated VTE.

Incidence of (A) recurrent VTE and (B) major bleeding in select randomised clinical trials of LMWH for the treatment and secondary prevention of VTE in.

Disease Burden of VTE Phases of VTE Treatment.

Taking the "Cryptogenic" Out of Cryptogenic Stroke

At the Crossroads of Coagulation

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

Treatment algorithm. Treatment algorithm. (A) Suggested treatment algorithm for symptomatic and incidental DVT or PE in cancer patients. (B) Suggested.

Potential protocol for the treatment of pulmonary embolism (PE), incorporating direct oral anticoagulants (OACs). Potential protocol for the treatment.

What's New in NOACs in AF?.

Treating Pulmonary Embolism Today

Presentation transcript:

A Case Challenge: Anticoagulant Choices for Acute PE

Case Patient Presentation

A Patient With Acute Dyspnea High Clinical Probability of PE

Differential Diagnosis Next Step?

A Patient With Acute Dyspnea Heparin Anticoagulation

Simplified PESI Score for Assessing the Likelihood of PE-Related Death

Acute PE: Based on Early (Intermediate) Mortality Risk Risk Parameters and Scores

ESC 2014 PE Anticoagulation Recommendations

NOACs VTE Acute Treatment Trials

Duration of VTE Treatment

Duration of Anticoagulant Therapy Factors Influencing Decision

NOACs VTE Extended Treatment Trials

Goals of VTE treatment